



Faculty of Science
Zoology department

Hematological and Biochemical Studies on the Effect of Statins (Lipitor) on Male Albino Rats

A Thesis

Submitted in Partial Fulfillment for the Degree of Master
of Science in Zoology

By

MARWA HUSSEIN AHMED REKABY

B.Sc.2006

Supervisors

Prof. Nefissa Hussein Meky

Professor of Physiology

Zoology Department

Faculty of Science – Ain Shams University

Prof. Dina Adel Fouad

Consultant of clinical pathology

Faculty of Medicine – Ain Shams University

Ain Shams University Specialized Hospital

Asmaa Ahmed Mahmoud

Lecturer of Physiology

Zoology department

Faculty of Science – Ain Shams University

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدقة الله العظيم

سورة البقرة الآية: ٣٢

Approval Sheet

Name: Marwa Hussein Ahmed Rekaby.

Title : Hematological and Biochemical Studies on The
Effect of Statins (Lipitor) on Male Albino Rats.

Scientific Degree: Master Degree of Science.

Board of Scientific Supervisors

Professor Dr. Nefissa Hussein Meky.

Professor of physiology,
Zoology department, Faculty of Science,
Ain Shams University.

Professor Dr. Dina Adel Fouad.

Professor of Clinical pathology,
Faculty of Medicine,
Ain Shams University.

Dr. Asmaa Ahmed Mahmoud.

Lecturer of Physiology,
Zoology department, Faculty of Science,
Ain Shams University.



Acknowledgement

*First and foremost, I feel always indebted to **Allah**, the Most Beneficent and merciful. I can do nothing without Him.*

I would like to express my deep gratitude and thanks to my supervisors for their help, encouragement, continuous advice and expert supervision to bring this thesis to more than satisfactory. They are always patient, perfect in work organization and their advisors.


*Great thanks to **Prof.Dr. Nefissa Hussein Meky**, Prof. of Physiology, Zoology Department, Faculty of Science, Ain Shams University, for suggesting the subject of this work, and valuable advice.*

*Very Special thanks to **Prof.Dr.Dina Adel Fouad**, Prof. of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her generous help and great support throughout the whole work,*

*Special thanks to **Dr.Aasma Ahmed Mahmoud**, Lecturer of Physiology, Zoology Department, Faculty of Science, Ain Shams University, for her help and cooperation.*

*Great thanks to Zoology Department and all my colleagues in for their assistance and support particularly, **Dr. Yomna Ibrahim**, and **Dr.Eman Ali**.*

*Deep thanks to Associate **Prof. Hoda Gmal El-Den Hejazy**, Associate Prof. of physiology, Faculty of Science, Ain Shams University, for her contribution in the idea of thesis.*





 **Marwa Hussein Ahmed Rekaby**



*First and foremost, I feel always
indebted to **Allah***

*Deep thanks and great full to my whole family
especially my **dear mother** the center of my life, **dear**
father the best father in the world and my kind
brother for everything they have done for me.*

*Very especial and great thanks to my small family dear
husband **Sherif** and to light of my eyes my lovely
children **Adam** & **Retal** for their patience and
encouragement.*

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	i
List of Tables.....	iv
List of Figures	v
Abstract	viii
Introduction	1
Aim of the work.....	3
Review of Literature	4
Materials and Methods.....	33
Results.....	50
Discussion	100
Summary	113
References	118
Arabic Summary	—

List of Abbreviations

Abbr.	Full-term
ADP	Adenosine diphosphate
AI	Atherogenic index
APC	Activated protein C
Apo A-I	Apolipoprotein A-I
Apo A-II	Apolipoprotein A-II
APTT	Activated partial thromboplastin time
AT III	Antithrombin activity
AT1	Angiotensin type1 receptor
ATP ase	Adenosine triphosphatase
CBC	Complete blood picture
CE	Cholesterol esterase
CHD	Coronary heart disease
CO	Cholesterol oxidase
CRI	Coronary artery index
CYP2C9	Cytochrome P2C9
CYP3A	Cytochrome P3A
CYP3A4	Cytochrome P3A4
CYP450	Cytochrome P450
DHBS	3,5-dichloro-2-hydroxybenzenesulfonic acid
DSBmT	N,N-bis (4-sulpho butyl)-m-Toluidine-disodium
EDTA	Ethylenediaminetetraacetic acid
eNOS	Endothelial nitric oxidase
EPCR	Endothelial cell protein C receptors
ET-1	Endothelin-1
FDP	Fibrin degradation products
FFAs	Free fatty acids
FIB	Fibrinogen
Fig	Figure
FPP	Farnesylpyrophosphate
GG	Geranylgeranyl
GGPP	Geranylgeranylpyrophosphate

GGTI	Geranylgeranyl transferase inhibitor
GK	Glycerol kinase
GPO	Glycerophosphate oxidase
GTP	Guanosine triphosphate
HCD	High cholesterol diet
HDL-C	High Density Lipoprotein Cholesterol
HDL-D	High Density Lipoprotein Cholesterol detergent
HGB	Hemoglobin
HMG-CoA	3-hydroxy-3-methylglutaryl coenzyme A
HPO	Horseradish Peroxidase
IL	Interleukin
INR	International normalized range
L0	Liquid ordered
LA	Lupus anticoagulants
Ld	Liquid domains
LDL-C	Low Density Lipoprotein Cholesterol
LDL-D	Low Density Lipoprotein Cholesterol detergent
LfA-1	Leukocyte function antigen-1
LPS	Lipopolysaccharide
mg/dl	Milligram/deciliter
mg/kg	Milligram/kilogram
MHC	Major histocompatibility complex
MI	Myocardial infarction
min	Minute
MM	Mill mole
ND	Normal diet
nm	Nanometers
NO	Nitric oxide
PAI-1	Plasminogen activator inhibitor-1
PAR-1	Plasminogen activator receptor-1
PAS	Periodic Acid-Schiff
PBS	Phosphate buffer saline
PL	Phospholipid
PLT	Platelets
PMSF	Phenyl methyl sulfonyl fluoride
PMV	Platelets mean volume

PP	Pyrophosphate
PT	Prothrombin time
PTT	Partial thromboplastin time
PVD	Peripheral vascular disease
RBCs	Red blood cells
RCT	Reverse cholesterol transport
RDW	Red cell distributionwidth
rpm	Revolutions per minute
RVV	Russell's viper Venom
TAFI	Thrombin2 activatable fibrinolysis inhibitor
TC	Total cholesterol
TF	Tissue factor
TFPI	Tissue factor pathway inhibitors
TG	Triglyceride
TM	Thrombomodulin
TNF	Tumor necrosis factor.
t-PA	Tissuetype plasminogen activator
TXA2	Thromboxane A2
VLDL	Very Low Density Lipoprotein Cholesterol
WBCs	White blood cells
α2AP	Alpha-2 antiplasmin
4-AAP	4-aminoantipyrine.

List of Tables

Table No.	Title	Page No.
Table (1):	Body Weights (g) at 1 st day, after 12 weeks and at the end of the experiment (after 16 weeks)	51
Table (2):	Serum triglycerides, total cholesterol, HDL-cholesterol & LDL-cholesterol concentrations.	56
Table (3):	Atherogenic index, coronary artery index, RBCs membrane total lipids and cholesterol values.	65
Table (4):	RBCs count, Hb concentration, platelets count and WBCs count.	77
Table (5):	Prothrombin Time (PT), INR, and Partial Thromboplastin Time (APTT).	86
Table (6):	Serum Antithrombin III, Fibrinogen, Protein C & Protein S concentrations.	92

List of Figures

Figure No.	Title	Page No.
Figure (1):	The structure of plasma cell membrane	10
Figure (2):	The processes of coagulation and fibrinolysis.....	12
Figure (3):	Protein C activation and expression of APC's multiple activities	17
Figure (4):	A simplified Draw of the Protein(C) System included Protein (S).....	20
Figure (5):	Statin structure	23
Figure (6):	Pleiotropic effects of statins.....	28
Figure (7):	Chemical Structure of Atorvastatin.....	31
Figure (8):	Box plot is showing the median body weight at 1 st day in the five studied groups.....	52
Figure (9):	Box plot is showing the median body weight at week 12 in the five studied groups.....	53
Figure (10):	Box plot is showing the median body weight at week 16 in the five studied groups.....	54
Figure (11):	The median body weight tracking through the experiment.	55
Figure (12):	Box plot is showing the total cholesterol level (TC) in the five studied groups.	57

Figure (13):	Box plot is showing the triglyceride level (TG) in the five studied groups.	59
Figure (14):	Box plot is showing the high density lipoprotein (HDL-C) in the five studied groups.	61
Figure (15):	Box plot is showing the low density lipoprotein (LDL-C) in the five studied groups.	63
Figure (16):	Box plot is showing the atherogenic index (AI) value in the five studied groups.	66
Figure (17):	Box plot is showing the coronary artery index (CRI) value in the five studied groups.	67
Figure (18):	Box plot is showing red blood cells membrane lipid (total lipid) in the five studied groups.	69
Figure (19):	Box plot is showing red blood cells membrane cholesterol level in the five studied groups.	71
Figure (20a):	RBCs membrane protein electrophoresis after 12 weeks of induces hyper-cholesterolemia in the current experiment.	73
Figure (20b):	RBCs membrane protein electrophoresis at the end of the experiment (after 12 weeks of induce hypercholesterolemia then 4 weeks treatment with atorvastatin) in the current experiment.	76

Figure (21):	Box plot showing red blood cells count (RBCs) in the five studied groups.....	78
Figure (22):	Box plot showing hemoglobin level (Hb) in the five studied groups.	80
Figure (23):	Box plot showing the platelets count (PLT) value in the five studied groups.	82
Figure (24):	Box plot showing white blood cells count (WBCs) in the five studied groups.	84
Figure (25):	Box plot is showing the prothrombin time (PT) in the five studied groups.	87
Figure (26):	Box plot is showing the INR value in the five studied groups.	88
Figure (27):	Box plot is showing the activated partial thromboplastin time (APTT) in the five studied groups.	90
Figure (28):	Box plot is showing the antithrombin III (ATIII) level in the five studied groups.	93
Figure (29):	Box plot is showing the fibrinogen level (FIB) in the five studied groups. Box represents the interquartile range.	95
Figure (30):	Box plot is showing the protein C concentration in the five studied groups.	97
Figure (31):	Box plot is showing the protein S concentration in the five studied groups.	99

Abstract

Atorvastatin (Lipitor) is one of the statins that have been known for their lipid-lowering effects, as well as their pleiotropic functions. The current study aimed to evaluate some pleiotropic effects of 20, 40, and 80 mg/kg b.wt of atorvastatin, orally administered to hypercholesterolemic male rats, daily for 4 weeks. The changes in body weights were tracked throughout the experiment. The study investigated serum lipid profile, atherogenic and coronary artery indices. Regarding erythrocytes membranes fluidity, erythrocytes membrane lipids and cholesterol were estimated, in addition to complete blood count and coagulation tests including, prothrombin time and partial prothrombin time. The Anticoagulant factors fibrinogen, antithrombin III, protein C, and protein S were also assessed. High-intense doses (40 and 80 mg/kg b.wt) of atorvastatin attenuated obesity, hypercholesterolemia, hypertriglyceridemia and LDL-C concentrations. Moreover, these doses of atorvastatin reduced erythrocytes membranes lipid and cholesterol levels. Further, both doses attenuated antithrombin III, protein-C and-S, and platelets count in comparison with untreated hypercholesterolemic rats. In conclusion, high-intense doses of atorvastatin exhibited anti-obesity and lipid-lowering effects. Moreover, these doses also showed pleiotropic potentials represented by improvement of fluidity of erythrocytes membranes, reduction of coagulation and thrombosis development, which would prevent future incidence of stroke and other cardiovascular diseases.

Key words: Atorvastatin, Hypercholesterolemia, Erythrocytes membranes, fluidity, antithrombotic effect.

Introduction

Obesity is correlated to increased inflammatory cytokines as well as a hypercoagulability status, which results in impairment in vascular and cardiac functions. Inhibiting those factors through therapeutic implications would attenuate the expected metabolic derangements (**Dirlewanger et al., 2015**), such as: atherosclerosis, hypertension, and other lipids abnormalities. There are many drugs for treatment of hypercholesterolemia, but statins are the most common drug. Statins are the 3-hydroxy-3-methylglutaryl (HMG)-Coenzyme A reductase inhibitor and have been evidenced to be potent agents in the management of hyperlipidemia (**Miyagishima et al., 2007**) and in the prevention of atherosclerotic vascular disease, especially coronary artery disease (**Morrissey, 2009**).

Statins exhibit several vascular effects, including antithrombotic properties that are not related to changes of lipid profile. Abundant experimental and clinical evidence has resulted in the widely accepted concept of cholesterol-independent pleiotropic effects produced by statins that include alteration of endothelial dysfunction, leading to increased nitric oxide (NO) bioavailability (**Undas et al., 2005**), regulation of angiogenesis, and reduction of inflammatory response via binding to novel allosteric site within the leukocyte function antigen-1-(LFA-1)-mediated